Wonder
Sign up
Log in
Research Outline
Prepared for Michael B. | Delivered December 17, 2019
BMS-Celgene Press Releases
Review your project details
Goals
Obtain press releases that are related to the BMS/Celgene merger on a broader scale.
View less
Early Findings
BMS-Celgene Press Releases
Bristol-Myers and Celgene's Liso-Cel
With Bristol-Myers Squibb's acquisition of Celgene, the former was able to also acquire the "
CAR-T therapy
l
i
s
o
c
a
b
t
a
g
e
n
e
m
a
r
a
l
e
u
c
e
l
(
l
i
s
o
-
c
e
l
)" medication.
BMS stated that they got
positive results
for this medication from three studies.
The announcement was made during the
American Society of Hematology
(ASH) Annual Meeting.
BMS Investors' Bet
After the acquisition, BMS investors lobbied for a separately-traded
contingent value right (CVR)
.
However, the CVR will only be beneficial i
f three highly promising medications
will be released for sale.
This is then considered as a
high-risk stake
.
OTEZLA Divestiture
BMS has made it known that
Celgene
has reached a deal with
A
m
g
e
n
.
Under the deal, the global license for OTEZLA® (
a
p
r
e
m
i
l
a
s
t
) will be bought by
A
m
g
e
n
for $13.4 billion.
This is linked to the acquisition of Celgene by BMS.
BMS has stated in the past that it has decided to sell off OTEZLA as part of an ongoing regulatory approval procedure.
View less